Table 2 Comparison of different stages of AKI in each group
Group | Total AKI occur [n (%)] | AKI stage I occur [n (%)] | AKI stage II occur [n (%)] | AKI stage III occur [n (%)] | P-value |
|---|---|---|---|---|---|
Age (y) | |||||
65–75 y | 35 (32.4) | 16 (45.7) | 13 (37.1) | 6 (17.1) | 0.881 |
> 75 y | 45 (42.1) | 18 (40.0) | 17 (37.8) | 10 (22.2) | |
Sex | |||||
Male | 57 (38.5) | 27 (47.4) | 19 (33.3) | 11 (19.3) | 0.955 |
Female | 23 (34.3) | 11 (47.8) | 7 (30.4) | 5 (21.7) | |
APACHEII score | |||||
< 10 | 5 (14.3) | 3 (60.0) | 1 (20.0) | 1 (20.0) | 0.157 |
10–20 | 36 (34.6) | 20 (55.6) | 11 (30.6) | 5 (13.9) | |
> 20 | 39 (51.3) | 11 (28.2) | 18 (46.2) | 10 (25.6) | |
Norepinephrine | |||||
No | 16 (25.4) | 11 (68.8) | 3 (18.8) | 2 (12.5) | 0.028 |
≤ 0.1 μg/kg/min | 35 (35.7) | 18 (51.4) | 12 (34.3) | 5 (14.3) | |
> 0.1 μg/kg/min | 29 (53.7) | 7 (22.6) | 13 (48.4) | 9 (29.0) | |
Infection types | |||||
Pneumonia | 35 (37.6) | 16 (45.7) | 14 (40.0) | 5 (14.3) | 0.545 |
BSIs | 20 (40.8) | 5 (25.0) | 9 (45.0) | 6 (30.0) | |
Intestinal infection | 13 (34.2) | 6 (46.2) | 4 (30.8) | 3 (23.1) | |
Other | 12 (34.3) | 7 (58.3) | 3 (25.0) | 2 (16.7) | |
Responsible pathogens | |||||
K.P | 32 (42.7) | 11 (34.4) | 13 (40.6) | 8 (25.0) | 0.971 |
P.A | 20 (35.1) | 10 (50.0) | 6 (30.0) | 4 (20.0) | |
A.B | 7 (30.4) | 3 (42.9) | 3 (42.9) | 1 (14.3) | |
E.coli | 8 (33.3) | 4 (50.0) | 3 (37.5) | 1 (12.5) | |
Other | 13 (36.1) | 6 (46.2) | 5 (38.5) | 2 (15.4) | |
Polymyxin B daily dose | |||||
1.5 mg/kg/d | 17 (26.2) | 10 (58.8) | 5 (29.4) | 2 (11.8) | 0.385 |
2.0 mg/kg/d | 36 (37.5) | 26 (56.5) | 13 (28.3) | 7 (15.2) | |
2.5 mg/kg/d | 27 (50.0) | 9 (34.6) | 10 (38.5) | 7 (26.9) | |
Initial treatment | |||||
Yes | 32 (34.0) | 13 (40.6) | 13 (40.6) | 6 (18.8) | 0.894 |
No | 48 (39.7) | 21 (43.8) | 17 (35.4) | 10 (20.8) | |
Polymyxin B Duration (d) | |||||
3–7 d | 13 (20.3) | 9 (76.9) | 2 (15.4) | 2 (15.4) | 0.027 |
8–14 d | 27 (37.0) | 15 (55.6) | 8 (29.6) | 4 (14.8) | |
> 14 d | 40 (51.3) | 10 (25.0) | 20 (50.0) | 10 (25.0) | |
Polymyxin B monotherapy | |||||
Yes | 10 (32.3) | 6 (60.0) | 3 (30.0) | 1 (10.0) | 0.457 |
No | 70 (38.0) | 28 (40.0) | 27 (38.6) | 15 (21.4) | |
Polymyxin B combination | |||||
Combined Carbapenems | 16 (40.0) | 5 (31.3) | 7 (43.8) | 4 (25.0) | 0.889 |
Combined Tigecycline | 20 (37.7) | 7 (35.0) | 9 (45.0) | 4 (20.0) | |
Tigecycline + fosfomycin | 12 (35.3) | 5 (41.7) | 4 (33.3) | 3 (25.0) | |
Carbapenems + tigecycline | 10 (45.4) | 4 (40.0) | 3 (30.0) | 3 (30.0) | |
Other | 12 (34.3) | 7 (58.3) | 4 (33.3) | 1 (8.30) | |
Microbiological eradication | |||||
Yes | 25 (26.3) | 16 (64.0) | 6 (24.0) | 3 (12.0) | 0.032 |
No | 55 (45.8) | 18 (32.7) | 24 (43.6) | 13 (23.6) | |
Clinical outcome | |||||
Cure | 22 (20.2) | 15 (68.2) | 5 (22.7) | 2 (9.1) | 0.018 |
Failure | 58 (54.7) | 19 (32.8) | 25 (43.1) | 14 (24.1) | |
Prognosis | |||||
Survival | 15 (18.8) | 9 (60.0) | 4 (26.7) | 2 (13.3) | 0.328 |
Death | 65 (52.4) | 25 (38.5) | 26 (40.0) | 14 (21.5) | |
AKI recovery | |||||
Yes | 28 (35.0) | 16 (47.1) | 10 (33.3) | 2 (12.5) | 0.035 |
No | 52 (65.0) | 18 (52.9) | 20 (66.7) | 14 (87.5) | |